Overview

The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-30

Target enrollment:

Participant gender:

Summary

Randomized, open-label, multicenter study to compare the efficacy and safety of Upadacitinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).

Phase:

PHASE2

Details

Lead Sponsor:

Peking University People's Hospital

Collaborators:

Beijing Aerospace General Hospital
Beijing Hospital
Beijing Tongren Hospital
Navy General Hospital, Beijing
Qilu Hospital of Shandong University

Treatments:

Dexamethasone
upadacitinib